Involvement of TLR4 in oxidized LDL/β2GPI/Anti-β2GPI-induced transformation of macrophages to foam cells

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 11, 2014, Pages 1140-1151

  Zhang, Xiaolei ^a,b,c   Xie, Yachao ^b   Zhou, Hong ^a,b   Xu, Y ^b   Liu, Jingjing ^b   Xie, Hongxiang ^b   Yan, Jinchuan ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

^c ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Foam cells; NF kB; Oxidized LDL 2GPI anti 2GPI complex; TF; TLR4

Indexed keywords

BETA ACTIN; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; THROMBOPLASTIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; LOW DENSITY LIPOPROTEIN; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL STIMULATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOAM CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALE; MICROSCOPY; MOUSE; MRNA EXPRESSION ASSAY; NONHUMAN; PERITONEUM MACROPHAGE; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; STAINING; UPREGULATION; WESTERN BLOTTING; ANIMAL; C3H MOUSE; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; BETA 2-GLYCOPROTEIN I; CHEMOKINE CCL2; FOAM CELLS; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C3H; NF-KAPPA B; OXIDATION-REDUCTION; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911947253     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.24372     Document Type: Article

References (47)

1. Matsuura E, Kobayashi K, Tabuchi M, Lopez LR: Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res, 2006; 45: 466-486
2. Lundberg AM, Hansson GK: Innate immune signals in atherosclerosis. Clin Immunol, 2010; 134: 5-24
3. Moore KJ, Tabas I: Macrophages in the pathogenesis of atherosclerosis. Cell, 2011; 145: 341-355
4. Matsuura, E, Kobayashi, K, Inoue, K, Lopez, L, Shoenfeld, Y: Oxidized LDL/b2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus, 2005; 14: 736-741
5. Lopes-Virella MF, Virella G: Pathogenic Role of Modified LDL Antibodies and Immune Complexes in Atheroscle-rosis. J Atheroscler Thromb, 2013; 20: 743-754
6. Perrins CJ, Bobryshev YV: Current advances in under-standing of immunopathology of atherosclerosis. Vir-chows Arch, 2011; 458: 117-123
7. Lahoute C, Herbin O, Mallat Z, Tedgui A: Adaptive immunity in atherosclerosis: mechanisms and future ther-apeutic targets. Nat Rev Cardiol, 2011; 8: 348-358
8. Xia L, Zhou H, Hu L, Xie H, Wang T, Xu Y, Liu J, Zhang X, Yan J: Both NF-KB and c-Jun/AP-1 involved in anti-^2GPI/^2GPI-induced tissue factor expression in mono-cytes. Thromb Haemost, 2013; 109: 643-651
9. Matsuura E, Lopez LR: Are Oxidized LDL//?2-glycopro-tein I Complexes Pathogenic Antigens in Autoimmune-mediated Atherosclerosis ? Clin Dev Immunol, 2004; 11: 103-111
10. Kobayashi K: Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res, 2003; 44: 716-726
11. Kajiwara T, Yasuda T, Matsuura E: Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of anti-phospholipid syndrome. J Autoimmun, 2007; 29: 164-173
12. Hasu M, Thabet M, Tam N and Whitman SC: Specific loss of toll-like receptor 2 on bone marrow derived cells decreases atherosclerosis in LDL receptor null mice. Can J Physiol Pharmacol, 2011; 89: 737-742
13. Kawai T, Akira S: Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity, 2011; 34: 637-650
14. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M: Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A, 2004; 101: 10679-10684
15. Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL: Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol, 2003; 14: 437-445
16. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirk-land TN, Witztum JL: Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem, 2003; 278: 1561-1568
17. Walton KA, Hsieh X, Gharavi N, Wang S, Wang G, Yeh M, Cole AL, Berliner JA: Receptors involved in the oxi-dized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-Phosphor-ylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem, 2003; 278: 29661-29666
18. Walton KA, Cole AL, Yeh M, Subbanagounder G, Krutzik SR, Modlin RL, Lucas RM, Nakai J, Smart EJ, Vora DK, Berliner JA: Specific phospholipid oxidation prod-ucts inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol, 2003; 23: 1197-1203
19. Lundberg AM, Ketelhuth DFJ, Johansson ME, Gerdes N, Liu S, Yamamoto M, Akira S, Hansson GK: Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis. Cardiovasc Res, 2013; 99: 364-373
20. 2GPI-induced tissue factor expression in THP-1 cells. Clin Exp Immunol, 2011; 163: 189-198
21. Zhou H, Chen D, Xie H, Xia L, Wang T, Yuan W, Yan J: Activation of MAPKs in the anti-^2GPI/^2GPI-induced tissue factor expression through TLR4/IRAKs pathway in THP-1 cells. Thromb Res, 2012; 130: e229-e235
22. Howell KW, Meng X, Fullerton DA, Jin C, Reece TB, Cleveland JC, Jr.: Toll-like receptor 4 mediates oxidized LDL-induced macrophage differentiation to foam cells. J Surg Res, 2011; 171: e27-31
23. Murase Y, Kobayashi J, Nohara A, Asano A, Yamaaki N, Suzuki K, Sato H, Mabuchi H: Raloxifene promotes adi-pocyte differentition of 3T3-L1 cells. Eur J Pharmacol, 2006; 538: 1-4
24. Chantrathammachart P, Mackman N, Sparkenbaugh E, Wang JG, Parise LV, Kirchhofer D, Key NS, Pawlinski R: Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood, 2012; 120: 636-646
25. Majka DS, Liu K, Pope RM, Karlson EW, Vu TH, Teodorescu M, Chang RW: Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Inflamm Res, 2013; 62: 919-927
26. Libby P, Ridker PM, Hansson GK: Progress and chal-lenges in translating the biology of atherosclerosis. Nature, 2011; 473: 317-325
27. Kobayashi K, Matsuura E, Liu Q, Furukawa J, Kaihara K, Inagaki J, Atsumi T, Sakairi N, Yasuda T, Voelker DR, Koike T: A specific ligand for beta(2)-glycoprotein I medi-ates autoantibody-dependent uptake of oxidized low den-sity lipoprotein by macrophages. J Lipid Res, 2001; 42: 697-709
28. Liu Q, Kobayashi K, Furukawa J, Inagaki J, Sakairi N, Iwado A, Yasuda T, Koike T, Voelker DR, Matsuura E: Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for beta(2)-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res, 2002; 43: 1486-1495
29. Lopez D, Kobayashi K, Merrill JT, Matsuura E, Lopez LR: IgG autoantibodies against beta2-glycoprotein I com-plexed with a lipid ligand derived from oxidized low-den-sity lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol, 2003; 10: 203-211
30. Zhou H, Ling S, Yu Y, Wang T, Hu H: Involvement of annexin A2 in anti-beta2GPI/beta2GPI-induced tissue fac-tor expression on monocytes. Cell Res, 2007; 17: 737-739
31. Zhou H, Wang H, Li N, Yu Y, Huang H, Yan Y, Wang T: Annexin A2 mediates anti-beta 2 GPI/beta 2 GPI-induced tissue factor expression on monocytes. Int J Mol Med, 2009; 24: 557-562
32. Vaiopoulos AG, Papachroni KK, Papavassiliou AG: Colon carcinogenesis: Learning from NF-kappaB and AP-1. Int J Biochem Cell Biol, 2010; 42: 1061-1065
33. Santos MJ, Carmona-Fernandes D, Canhao H, Canas da Silva J, Fonseca JE, Gil V: Early vascular alterations in SLE and RA patients--a step towards understanding the associated cardiovascular risk. PLoS ONE, 2012; 7: e44668
34. Winckers K, ten Cate H, Hackeng TM: The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis. Blood Rev, 2013; 27: 119-132
35. Prasongsukarn K, Chaisri U, Chartburus P, Wetchabut K, Benjathummarak S, Khachansaksumet V, Maneerat Y: Phenotypic alterations in human saphenous vein culture induced by tumor necrosis factor-alpha and lipoproteins: a preliminary development of an initial atherosclerotic plaque model. Lipids Health Dis, 2013; 12: 132
36. Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR, Ballantyne CM: Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communi-ties study. Atherosclerosis, 2005; 183: 301-307
37. Mangale D, Kariuki SN, Chrabot BS, Kumabe M, Kelly JA, Harley JB, James JA, Sivils KL, Niewold TB: Familial aggregation of high tumor necrosis factor alpha levels in systemic lupus erythematosus. Clin Dev Immunol, 2013; 2013: 267-430
38. Xie H, Zhou H, Wang H, Chen D, Xia L, Wang T, Yan J: Anti-beta(2)GPI/beta(2)GPI induced TF and TNF-alpha expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. Mol Immunol, 2013; 53: 246-254
39. Fragoso-Loyo H, Atisha-Fregoso Y, Llorente L, Sanchez-Guerrero J: Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychi-atric systemic lupus erythematosus. Rheumatology (Oxford), 2013; 52: 2218-2222
40. Hrycek E, Franek A, Blaszczak E, Dworak J, Hrycek A: Serum levels of selected chemokines in systemic lupus ery-thematosus patients. Rheumatol Int, 2013; 33: 2423-2427
41. Willis R, Seif AM, McGwin G Jr, Martinez-Martinez LA, Gonzalez EB, Dang N, Papalardo E, Liu J, Vila LM, Rev-eille JD, Alarcon GS, Pierangeli SS: Effect of hydroxychlo-roquine treatment on pro-inflammatory cytokines and dis-ease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus, 2012; 21: 830-835
42. Cole JE, Navin TJ, Cross AJ, Goddard ME, Alexopoulou L, Mitra AT, Davies AH, Flavell RA, Feldmann M, Monaco C: Unexpected protective role for Toll-like recep-tor 3 in the arterial wall. Proc Natl Acad Sci U S A, 2011; 108: 2372-2377
43. Zimmer S, Steinmetz M, Asdonk T, Motz I, Coch C, Hart-mann E, Barchet W, Wassmann S, Hartmann G, Nickenig G: Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res, 2011; 108: 1358-1366
44. Richards MR, Black AS, Bonnet DJ, Barish GD, Woo CW, Tabas I, Curtiss LK, Tobias PS: The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice. Innate Immun, 2013; 19: 20-29
45. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T: Involvement of beta 2-glycoprotein I and anti-cardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol, 1997; 107: 569-573
46. Greco TP, Coni-kelly AM, Anthony JR, Greco T Jr, Doyle R, Boisen M, Kojima K, Matsuura E, Lopez LR: Oxi-dized-LDL/ beta 2-Glycoprotein I complexes are associ-ated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes. Am J Clin Pathol, 2010; 133: 737-743
47. Lopez LR, Salazar-Paramo M, Palafox-Sanchez C, Hurley BL, Matsuura E, Garcia-De La Torre I: Oxidized low-density lipoprotein and beta 2-Glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus, 2006; 15: 80-86